Delcath Systems, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Mon, November 9, 2026 at 12:48 PM EST 3 min read NVDA -5.31% DCTH +28.03% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Record third-quarter revenue of $35.1 million, a 71% increase year-over-year, was driven by strong adoption of HEPZATO KIT and a high rate of approximately 0.6 new patient starts per site per month.
The company reached a critical milestone of 1,000 commercial HEPZATO treatments in the U.S., signaling that the therapy is becoming firmly incorporated into the standard of care at experienced centers.
Management attributes growth to the increasing normalization of combination therapy, where HEPZATO is used alongside systemic treatments rather than as a mutually exclusive alternative.
Operational capacity at existing centers has been expanded by incentivizing the creation of backup teams for perfusionists, anesthesiologists, and interventional radiologists to mitigate scheduling bottlenecks.
The addition of AdventHealth to the network is strategically significant due to its scale as one of the nation's largest integrated health systems, providing a robust internal referral platform for metastatic uveal melanoma.
Strategic pipeline expansion is focusing on oxaliplatin-based PHP because oncologists are highly familiar with the agent, potentially allowing for earlier-line usage in colorectal and other GI cancers.
Full-year 2026 revenue guidance was raised to a range of $115 million to $117 million, reflecting an expected HEPZATO KIT volume growth of at least 41% over 2025.
The timeline for the Phase II colorectal trial interim analysis has been accelerated to mid-2027, moving up from previous estimates of late 2027 due to enrollment progress.
Q4 2026 guidance assumes a sequential revenue step-down to between $25.8 million and $27.8 million, primarily due to an estimated loss of two weeks of treatment time for holiday scheduling.
The company plans an IND submission for cholangiocarcinoma in early 2027 and expects to complete preclinical development for an oxaliplatin-based PHP program by mid-2027.
Management expects R&D expenses to continue increasing quarter-over-quarter into 2027 as clinical trial activity and headcount ramp up to support the expanding pipeline.
The company achieved positive operating cash flow of $8.2 million and adjusted EBITDA of $11.5 million, demonstrating significant operating leverage in the commercial model.
Delcath ended the quarter with $104.3 million in cash and investments and no debt, providing flexibility for ongoing research and network investment.
While the U.S. network reached 33 active centers, management aims to have at least 36 centers activated by the end of 2026, pending patient scheduling and site readiness.
Enrollment in the breast cancer trial remains slower than initially anticipated, though multiple sites are now recruiting across Europe and the U.S.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management cited combination therapy adoption, increased patient awareness, and the implementation of backup clinical teams as the primary drivers for the Q3 beat.
The conservative Q4 outlook reflects historical trends of fewer new patient starts in the final quarter and the practical reality of holiday-related scheduling cancellations.
Oncologists view oxaliplatin as a better biological match for colorectal liver metastases and are more comfortable using it as a standard backbone agent.
By delivering high-dose oxaliplatin regionally while reducing systemic exposure, Delcath aims to incorporate the therapy into standard FOLFOX regimens without increasing cumulative toxicity.
Management anticipates that the final 340B rules will be net neutral to net positive for the company's average selling price (ASP).
The regulatory changes are not expected to have any material impact on treatment volumes.
